Mela Sciences' MelaFind goes to panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's General and Plastic Surgery Devices advisory panel will meet Nov. 18 to discuss a pre-market approval application for Mela Sciences' non-invasive computer vision system to aid in the detection of melanoma. The computer-controlled multi-spectral dermoscope uses light to image skin through a thin layer of liquid, making lesions under the skin surface visible to the eye; a digital camera inside the probe captures images and differentiates lesions for melanoma risk using pattern recognition software. The panel review was postponed from Aug. 26 to allow FDA more time to arrange the meeting (1"The Gray Sheet" July 26, 2010)
You may also be interested in...
FDA Panel Narrowly Endorses Mela Sciences’ Melanoma Detection System
An FDA advisory panel Nov. 18 narrowly endorsed Mela Sciences’ MelaFind melanoma detection system, voting 8-7, with one abstention, that the benefits outweigh any risks.
Spectral Molecular Imaging Readies IDE For Melanoma Detection Trial
Spectral Molecular Imaging will submit an investigational device exemption application to FDA within three months for its SkinSpect system to aid early melanoma detection.
Regulatory News In Brief
Mela Sciences panel delay: FDA has postponed advisory committee review of Mela Sciences' MelaFind, a non-invasive computer vision system to aid in the detection of melanoma, from Aug. 26 to sometime in November. FDA told the firm it needs more time to arrange the meeting, the firm said July 21 (1"The Gray Sheet" June 28, 2010)